Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.

نویسندگان

  • Srdan Verstovsek
  • Ayalew Tefferi
  • Hagop Kantarjian
  • Taghi Manshouri
  • Raja Luthra
  • Animesh Pardanani
  • Alfonso Quintás-Cardama
  • Farhad Ravandi
  • Pat Ault
  • Carlos Bueso-Ramos
  • Jorge E Cortes
چکیده

PURPOSE Patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) that are refractory to standard therapies are difficult to manage and have significantly shortened life expectancy. EXPERIMENTAL DESIGN CD52 is a surface glycoprotein highly expressed on eosinophils. We treated 11 patients with advanced HES/CEL with alemtuzumab, a humanized anti-CD52 monoclonal antibody. Alemtuzumab was administered, in general, first in escalating doses (5, 10, 30 mg i.v. on days 1-3), then at the tolerated dose thrice per week for a total of 12 doses. Patients with complete hematologic response (CHR; normal percent and absolute eosinophil count) were allowed to continue therapy once weekly as maintenance. RESULTS Ten patients (91%) achieved CHR after a median of 2 weeks (0.5-5 weeks) of therapy. Bone marrow eosinophilia resolved in four of seven evaluable patients. The median duration of CHR was 3 months (1.5-17+ months). Seven of the 10 CHR patients relapsed, five while off-therapy. Two patients achieved second CHR upon alemtuzumab rechallenge. Three patients experienced mild infusion-related symptoms, two developed cytomegalovirus reactivation requiring therapy, and one developed orbital lymphoma that was successfully treated. CONCLUSIONS Our limited experience suggests alemtuzumab to be a valuable therapy for advanced HES or CEL, refractory to standard therapies, and supports the clinical evaluation of alemtuzumab in a larger trial.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.

DISEASE OVERVIEW The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. DIAGNOSIS Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1,500/mm(3) and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia,...

متن کامل

Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Acquired eosinophilia is operationally categorized into secondary, clonal, and idiopathic types. Causes of secondary eosinophilia include parasite infections, allergic or vasculitis conditions, drugs, and lymphoma. Clonal eosinophilia is distinguished from idiopathic eosinophilia by the presence of histologic, cytogenetic, or molecular evidence of an underlying myeloid malignancy. The World Hea...

متن کامل

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome

Chronic eosinophilic leukemia, not otherwise specified can be difficult to distinguish from idiopathic hypereosinophilic syndrome according to the current World Health Organization guideline. To examine whether the morphological features of bone marrow might aid in the differential diagnosis of these two entities, we studied a total of 139 patients with a diagnosis of chronic eosinophilic leuke...

متن کامل

Cardiac Involvement in a Patient with Eosinophilia and Inversion of Chromosome 16(p13q22): A Case of Chronic Eosinophilic Leukemia or AML-M4EO?

Any chronic hypereosinophilic state, including eosinophilic leukemia, reactive eosinophilia and idiopathic hypereosinophilic syndrome may be complicated by the end-organ damaging effects of eosinophilic degranulation, especially cardiac involvement. Several cytogenetic abnormalities that have prognostic and even therapeutic implications, have been described in patients with different variants o...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical cancer research : an official journal of the American Association for Cancer Research

دوره 15 1  شماره 

صفحات  -

تاریخ انتشار 2009